Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1210190

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1210190

COVID-19 Drug Associated APIs Global Market Report 2023

Published: Pre-Order
PAGES: 250 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

Contact us about how to customize the report with add-on data.

COVID-19 Drug Associated APIs Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on COVID-19 drug associated apis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for COVID-19 drug associated apis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The COVID-19 drug associated apis market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Class: Antimalarials; Bronchodilators; Antibiotics; Antivirals; Other Drug Class

2) By Synthesis Type: Synthetic; Biotech

3) By Business Mode: Captive API; Merchant API

Companies Mentioned: Dr. Reddy's Laboratories; Lianyungang Guike Pharmaceutical; Alembic Pharmaceutical; Wockhardt Ltd; Sandoz Srl

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the COVID-19 drug-associated APIs market are: Dr. Reddy's Laboratories, Lianyungang Guike Pharmaceutical, Alembic Pharmaceutical, Wockhardt Ltd, Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical (Haimen) Co Ltd, and Yatai Pharma.

The global COVID-19 drug-associated APIs market is expected to grow from $5.55 billion in 2021 to $5.99 billion in 2022 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The COVID-19 drug-associated APIs market is expected to reach $7.55 billion in 2026 at a CAGR of 6%.

The COVID-19 drug associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

COVID-19 drug-associated APIs refer to the active pharmaceutical components that are employed in the production of COVID-19 medications. Chemicals called active pharmaceutical components serve as the foundation for pharmaceutical drugs and medicines and are responsible for pharmacological activity in the human body.

North America is the largest region in the COVID-19 drug-associated APIs market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the COVID-19 drug-associated APIs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main classes of drugs in COVID-19 drug-associated APIs are antimalarials, bronchodilators, antibiotics, antivirals, and others. Antimalarial drugs, or simply antimalarials, are antiparasitic chemical agents which can be utilized to cure or prevent malaria. They are generally organically sourced. The different types of drugs include generic, branded, and d and involve various modes of business such as captive API and merchant API.

High demand for some antiretrovirals, antimalarials, sedatives, bronchodilators and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs. Active pharmaceutical ingredients (APIs) are the biologically active component used in manufacturing pharmaceutical drugs. Remdesivir and Favipiravir are two common antiviral medications used currently for the treatment of COVID-19 patients. Remdesivir is a medication approved for emergency use in the USA and Japan for the treatment of COVID-19 patients. Remdesivir gained emergency use authorization (EUA) from the FDA on May 1, 2020, based on its preliminary data showing a faster time to recovery in hospitalized patients with several diseases. Favipiravir, which is used to treat influenza in Japan, has also shown a positive effect on COVID patients. As COVID-19 is a respiratory ailment, the demand for bronchodilators spiked significantly. Therefore, the increasing demand for antivirals, antimalarials, and bronchodilators is projected to boost the demand for the COVID-19-associated drug APIs market over the forecast period.

The disruptions caused by the COVID-19 outbreak in the supply chain of medical products limited the growth of the COVID-19 drug-associated APIs market in the past few months. The source for APIs plays a crucial part in the strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, with nearly 30% of generic APIs used in the USA. The restrictions imposed on the export of pharma products owing to COVID-19 supply chain disruptions restricted the market growth. For instance, India imposed an export ban on 26 pharma products and medical devices in March 2020. The ban was imposed attributing to the supply chain disruptions on API and other bulk drugs due to restrictive measures such as lockdown and closure of factories in many countries across the globe to ensure that the disease spread is contained. Thus, shortages caused by the disruptions in supply chains and restrictions imposed on the export of pharma products impacted the growth of the COVID-19 drug-associated APIs market over the last few months.

Key players operating in the pharmaceutical industry that manufactures COVID-19 drug-associated APIs are focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of coronavirus cases across the globe. For instance, in March 2020, Alembic Pharmaceuticals Ltd announced that the company is ramping up the production for the company's production for azithromycin to 20 tons per month. Likewise, In April 2020, FUJIFILM Corporation announced the expansion of its manufacturing capacity and increase in the production of influenza antiviral Avigan Tablet (Favipiravir) by nearly 2.5 times by the end of July. Avigan is currently undergoing clinical trials testing its safety and efficacy for the treatment of COVID-19 patients.

In February 2020, Dr. Reddy Labs announced the acquisition of the branded generics business of Wockhardt for an amount of $242 million (INR 1,850 crore). The acquisition is expected to scale up the former company's presence in home markets including India, Nepal, Sri Lanka, Bhutan, and the Maldives. The Wockhardt business consists of a product portfolio of 62 brands in multiple therapy fields such as dermatology, neurology, respiratory, VMS, pain, gastroenterology, and vaccine. Wockhardt Ltd. was founded in 1999 and is a global biotechnology and pharmaceutical company based in Mumbai, India.

The countries covered in the COVID-19 drug-associated APIs market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The COVID-19 drug-associated APIs market research report is one of a series of new reports from The Business Research Company that provides COVID-19 drug-associated APIs market statistics, including COVID-19 drug-associated APIs industry global market size, regional shares, competitors with a COVID-19 drug-associated APIs market share, detailed COVID-19 drug-associated APIs market segments, market trends and opportunities, and any further data you may need to thrive in the COVID-19 drug-associated APIs industry. This COVID-19 drug-associated APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Product Code: r2043

Table of Contents

1. Executive Summary

2. COVID-19 Drug Associated APIs Market Characteristics

3. COVID-19 Drug Associated APIs Market Trends And Strategies

4. COVID-19 Drug Associated APIs Market - Macro Economic Scenario

4.1 COVID-19 Impact On COVID-19 Drug Associated APIs Market

4.2 Ukraine-Russia War Impact On COVID-19 Drug Associated APIs Market

4.3 Impact Of High Inflation On COVID-19 Drug Associated APIs Market

5. COVID-19 Drug Associated APIs Market Size And Growth

  • 5.1. Global COVID-19 Drug Associated APIs Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global COVID-19 Drug Associated APIs Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. COVID-19 Drug Associated APIs Market Segmentation

  • 6.1. Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Antimalarials
  • Bronchodilators
  • Antibiotics
  • Antivirals
  • Other Drug Class
  • 6.2. Global COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Synthetic
  • Biotech
  • 6.3. Global COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Captive API
  • Merchant API

7. COVID-19 Drug Associated APIs Market Regional And Country Analysis

  • 7.1. Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific COVID-19 Drug Associated APIs Market

  • 8.1. Asia-Pacific COVID-19 Drug Associated APIs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China COVID-19 Drug Associated APIs Market

  • 9.1. China COVID-19 Drug Associated APIs Market Overview
  • 9.2. China COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India COVID-19 Drug Associated APIs Market

  • 10.1. India COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan COVID-19 Drug Associated APIs Market

  • 11.1. Japan COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia COVID-19 Drug Associated APIs Market

  • 12.1. Australia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia COVID-19 Drug Associated APIs Market

  • 13.1. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea COVID-19 Drug Associated APIs Market

  • 14.1. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe COVID-19 Drug Associated APIs Market

  • 15.1. Western Europe COVID-19 Drug Associated APIs Market Overview
  • 15.2. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK COVID-19 Drug Associated APIs Market

  • 16.1. UK COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany COVID-19 Drug Associated APIs Market

  • 17.1. Germany COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France COVID-19 Drug Associated APIs Market

  • 18.1. France COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe COVID-19 Drug Associated APIs Market

  • 19.1. Eastern Europe COVID-19 Drug Associated APIs Market Overview
  • 19.2. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia COVID-19 Drug Associated APIs Market

  • 20.1. Russia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America COVID-19 Drug Associated APIs Market

  • 21.1. North America COVID-19 Drug Associated APIs Market Overview
  • 21.2. North America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA COVID-19 Drug Associated APIs Market

  • 22.1. USA COVID-19 Drug Associated APIs Market Overview
  • 22.2. USA COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America COVID-19 Drug Associated APIs Market

  • 23.1. South America COVID-19 Drug Associated APIs Market Overview
  • 23.2. South America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil COVID-19 Drug Associated APIs Market

  • 24.1. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East COVID-19 Drug Associated APIs Market

  • 25.1. Middle East COVID-19 Drug Associated APIs Market Overview
  • 25.2. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa COVID-19 Drug Associated APIs Market

  • 26.1. Africa COVID-19 Drug Associated APIs Market Overview
  • 26.2. Africa COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. COVID-19 Drug Associated APIs Market Competitive Landscape And Company Profiles

  • 27.1. COVID-19 Drug Associated APIs Market Competitive Landscape
  • 27.2. COVID-19 Drug Associated APIs Market Company Profiles
    • 27.2.1. Dr. Reddy's Laboratories
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Lianyungang Guike Pharmaceutical
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Alembic Pharmaceutical
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Wockhardt Ltd
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Sandoz Srl
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. COVID-19 Drug Associated APIs Pipeline Analysis

29. Key Mergers And Acquisitions In The COVID-19 Drug Associated APIs Market

30. COVID-19 Drug Associated APIs Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Historic And Forecast Inflation Rates
  • 31.4. Research Inquiries
  • 31.5. The Business Research Company
  • 31.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!